Lopixibat chloride

Drug Profile

Lopixibat chloride

Alternative Names: LUM-001; Maralixibat; SD-5613; SHP 625

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Childhood Liver Disease Research and Education Network; Pfizer; Shire
  • Class Azabicyclo compounds; Benzothiepins; Dioxoles; Hepatoprotectants; Onium compounds; Small molecules
  • Mechanism of Action Sodium-bile acid cotransporter-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary biliary cirrhosis; Alagille syndrome; Intrahepatic cholestasis; Primary sclerosing cholangitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alagille syndrome; Intrahepatic cholestasis; Primary biliary cirrhosis; Primary sclerosing cholangitis
  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 14 Dec 2017 Shire plans a phase III trial for Alagille syndrome (Shire pipeline, December 2017)
  • 27 Nov 2017 Shire plans a phase III trial for Intrahepatic Cholestasis in USA , (NCT03353454)
  • 24 Oct 2017 Additional efficacy data from a phase II trial in Intrahepatic cholestasis presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top